Prolonged Thromboprophylaxis Following Hip Replacement Surgery – Results of a Double-blind, Prospective, Randomised, Placebo-controlled Study with Dalteparin (Fragmin®)

Summary

Discontinuation of thromboprophylaxis a few days after surgery may unmask delayed hypercoagulability and contribute to late formation of deep venous thrombosis (DVT). To investigate whether thromboprophylaxis should be prolonged beyond the hospital stay, a prospective, double-blind randomised study was conducted in 308 patients. All patients received initial thromboprophylaxis with dalteparin, dextran and graded elastic stockings. On day 7, patients were randomised to receive dalteparin (Fragmin®) 5000IU once daily, or placebo, for 4 weeks. All patients were subjected to bilateral venography, perfusion ventilation scintigraphy and chest X-ray on days 7 and 35. Patients with venographically verified proximal DVT on day 7 were withdrawn from the randomised study to receive anticoagulant treatment. The overall prevalence of DVT on day 7 was 15.9%. On day 35, the prevalence of DVT was 31.7% in placebo-treated patients compared with 19.3% in dalteparin-treated patients (p = 0.034). The incidence of DVT from day 7 to day 35 was 25.8% in the placebo-treated group versus 11.8% in the dalteparin-treated group (p = 0.017). The incidence of symptomatic pulmonary embolism (PE) from day 7 to day 35 was 2.8% in the placebo-treated group compared with zero in the dalteparin-treated group. This included one patient who died from PE. No patients experienced serious complications related to the injections of dalteparin or placebo. This study shows that prolonged thromboprophylaxis with dalteparin, 5000 IU, once daily for 35 days significantly reduces the frequency of DVT and should be recommended for 5 weeks after hip replacement surgery.

• References

• 1 Nillius AS, Nylander G. Deep vein thrombosis after total hip replacement: a clinical and phlebographic study. Br J Surg 1979; 66: 324-326
• 2 Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Naim D, Bentley PG. Femoral vein thrombosis and total hip replacement. B M J 1977; 02: 223-225
• 3 Kalodiki E, Nicolaides AN, Al-Kutoubi A, Birch R, Harris N, Hunt D, Johnson J, Marx C. LMWH and LMWH plus graduated elastic compression for DVT prophylaxis in total hip replacement. Thromb Haemost 1993; 69 (Suppl. 06) 619
• 4 Dahl OE, Molnar I, Vinje A, Rø JS, Kierulf P, Andersen Å-B, Dalaker K, Prydz H. Studies on coagulation, fibrinolysis, kallikrein-kinin arid complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement. Thromb Res 1988; 50: 875-884
• 5 Dahl OE, Pedersen T, Kierulf P, Westwik Å-B, Lund P, Amesen H, Seljeflot I, Abdelnoor M, Lyberg T. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993; 70: 451-458
• 6 Dahl OE, Aspelin T, Amesen H, Seljeflot I, Kierulf P, Ruyter R, Lyberg T. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thrombopropylaxis after hip replacement surgery. Thromb Res 1995; 04: 299-306
• 7 MacNally MA, Molland RAB. Total hip replacement, lower limb blood flow and venous thrombogenesis. J Bone J Surg 1993; 75B: 640-644
• 8 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 9 Amesen H, Heilo A, Jakobsen E, Ly B, Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978; 203: 457-463
• 10 Müller C. Pulmonary scintigraphy. In: Treatment of venous thrombosis and pulmonary embolism. Norwegian Medicines Control Authority and Medical Products Agency. Sweden: 1995: 83-91
• 11 Biello DR, Mattar AG, McKnight RC, Siegel BA. Ventilation-perfusion studies in suspected pulmonary embolism. Am J Radiol 1979; 133: 1033-1037
• 12 Turpie AGG. Thromboprophylaxis in orthopaedic surgery. In: Thrombosis Clinical practice and perspectives. Stockholm: Kabi Pharmacia; 1993: 3-16
• 13 Bergqvist D. Long-term prophylaxis following orthopedic surgery. Haemostasis 1993; 23 (Suppl. 01) 27-31
• 14 Dahl OE, Aspelin T, Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coag Fibrinol 1995; 6: 709-717
• 15 Scurr HJ. How long after surgery does the risk of thromboembolism persist. Acta Chir Scand 1990; 556 (Suppl) 22-24
• 16 Tremaine MD, Choroszy CJ, Menking SA. Deep vein thrombosis in the total hip arthroplasty patient after hospital discharge. J Vase Technology 1991; 15: 205-206
• 17 Arcelus JI, Caprini JA, Traverso CL. Venous thromboembolism after hospital discharge. Semin Thromb Hemost 1993; 19: 142-146
• 18 Nylander G. Comments in reason for conflicting results of venography. Hemostasis 1993; 23 (Suppl. 01) 85-88
• 19 Lassen M, Borris L. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty - a placebo controlled study. Thromb Haemost 1995; 73: 1104
• 20 Bergqvist D. The post-discharge risk of venous thrombosis after hip replacement surgery and its management with enoxaparin. In: Emerging role of LMWH in venous thromboembolism. Paris: Rône-Polenc Rorer; 1995. 16.
• 21 Trowbridge A, Boese CK, Woodruff B, Brindley HH, Lowry WE, Spiro TE. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty. Clin Orthop Rel Res 1994; 299: 203-208
• 22 Planes A. Post hospital discharge occurence of deep vein thrombosis in patients undergoing total hip replacement: efficacy and safety of enoxaparin prevention. In: Emerging role of LMWH in venous thromboembolism. Paris: Rone-Polenc Rorer; 1995. 14.
• 23 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk Arch Surg. 1992; 127: 310-313
• 24 Hunter J, Frostick S. Dalteparin (Fragmin) for the prevention of early mortality after orthopaedic surgery. Thromb Haemost 1995; 73: 977